Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sheldon

Showing results (301-310 of 8,118) with videos related to

Pageof 812
Sort By:
Work (Reading, Mass.)|August 30, 2007
Evidence-based practice in occupational health: description and application of an implementation effectiveness modelMichael R Sheldon
Journal of Psychiatric Practice|March 25, 2024
How the Food and Drug Administration Drug Approval Process Relates to the Potential Approval of Intravenous Racemic Ketamine for Treatment-resistant Major DepressionSheldon H Preskorn
The American Journal of Managed Care|January 26, 2019
Burden of migraine and impact of emerging therapies on managed careSheldon J Rich
Journal of Psychiatric Practice|December 11, 2019
Drug-Drug Interactions (DDIs) in Psychiatric Practice, Part 7: Relative Receptor Binding Affinity as a Way of Understanding the Differential Pharmacology of Currently Available AntipsychoticsSheldon H Preskorn
Journal of Psychiatric Practice|May 5, 2022
How an Understanding of the Function of the Locus Coeruleus Led to Use of Dexmedetomidine to Treat Agitation in Bipolar Disorder: Example of Rational Development of Psychiatric MedicationsSheldon H Preskorn
Physical Therapy|October 10, 2015
Policy-Making Theory as an Analytical Framework in Policy Analysis: Implications for Research Design and Professional AdvocacyMichael R Sheldon
Journal of Psychiatric Practice|September 17, 2014
Clinical psychopharmacology and medical malpractice: the four DsSheldon H Preskorn
Journal of Psychiatric Practice|January 21, 2015
CNS drug development: lessons learned part 2. Symptoms, not syndromes as targets consistent with the NIMH research domain approachSheldon H Preskorn
Journal of Psychiatric Practice|September 30, 2017
CNS Drug Development: Lessons Learned Part 3: Psychiatric and Central Nervous System Drugs Developed Over the Last Decade-Implications for the FieldSheldon H Preskorn
Chemistry (Weinheim an Der Bergstrasse, Germany)|July 8, 2016
Biocatalysis and Biomass Conversion in Alternative Reaction MediaRoger A Sheldon
Pageof 812

Showing results (301-310 of 8,118) with videos related to

Sort By:
Pageof 812
Work (Reading, Mass.)|August 30, 2007
Evidence-based practice in occupational health: description and application of an implementation effectiveness modelMichael R Sheldon
Journal of Psychiatric Practice|March 25, 2024
How the Food and Drug Administration Drug Approval Process Relates to the Potential Approval of Intravenous Racemic Ketamine for Treatment-resistant Major DepressionSheldon H Preskorn
The American Journal of Managed Care|January 26, 2019
Burden of migraine and impact of emerging therapies on managed careSheldon J Rich
Journal of Psychiatric Practice|December 11, 2019
Drug-Drug Interactions (DDIs) in Psychiatric Practice, Part 7: Relative Receptor Binding Affinity as a Way of Understanding the Differential Pharmacology of Currently Available AntipsychoticsSheldon H Preskorn
Journal of Psychiatric Practice|May 5, 2022
How an Understanding of the Function of the Locus Coeruleus Led to Use of Dexmedetomidine to Treat Agitation in Bipolar Disorder: Example of Rational Development of Psychiatric MedicationsSheldon H Preskorn
Physical Therapy|October 10, 2015
Policy-Making Theory as an Analytical Framework in Policy Analysis: Implications for Research Design and Professional AdvocacyMichael R Sheldon
Journal of Psychiatric Practice|September 17, 2014
Clinical psychopharmacology and medical malpractice: the four DsSheldon H Preskorn
Journal of Psychiatric Practice|January 21, 2015
CNS drug development: lessons learned part 2. Symptoms, not syndromes as targets consistent with the NIMH research domain approachSheldon H Preskorn
Journal of Psychiatric Practice|September 30, 2017
CNS Drug Development: Lessons Learned Part 3: Psychiatric and Central Nervous System Drugs Developed Over the Last Decade-Implications for the FieldSheldon H Preskorn
Chemistry (Weinheim an Der Bergstrasse, Germany)|July 8, 2016
Biocatalysis and Biomass Conversion in Alternative Reaction MediaRoger A Sheldon
Pageof 812